Extended Release Buprenorphine in Correctional Settings Shows Increased Treatment Retention and Reduced Opioid Use

Findings from JCOIN’s New York University Research Hub Both the rate of opioid use and the rate of overdose following release from jail or prison are disproportionately high in justice-involved populations [1]. Although medications for opioid use disorder (MOUD) are proven to reduce the likelihood for post-release overdose, they are largely underutilized in correctional facilities…

Read More

JCOIN Research Update: Opioid Use Disorder Stigma, Discrimination, and Policy Attitudes in a National Sample of U.S. Young Adults

Stigma and attitudes about addiction contribute to the availability and accessibility of treatment for individuals with substance use disorders. A 2020 study from NORC at the University of Chicago and Indiana University sought to understand attitudes about opioid use disorder among 190 young adults aged 19-29 across the United States. Key Findings: The study found…

Read More

States Policies to Expand Access to Substance Use Disorder Treatment during COVID-19

New Data from JCOIN’s Brown University Clinical Research Center Source: PDAPS The Prescription Drug Abuse Policy System (PDAPS) is an online resource, developed by a team at the Center for Public Health Law Research at Temple University, through a supplement to JCOIN’s Brown University Clinical Research Center (Hub), that provides data and information on state…

Read More

Offering Buprenorphine Prior to Release from Jail May Reduce Recidivism

Findings from JCOIN’s Massachusetts Research Hub Individuals leaving incarceration with opioid use disorder (OUD) are at a high risk for overdose, recidivism, and adverse health outcomes. Providing medication for opioid use disorder (MOUD) prior to incarceration and post-release is effective in reducing negative outcomes. Existing studies tend to examine how the use of methadone and/or…

Read More

Issue Brief: Medications for Opioid and Alcohol Use Disorders: Research Insights for Criminal Justice Professionals

Key Takeaways Medications for Substance Use Disorders Are Effective Treatments. Methadone, buprenorphine, and naltrexone are FDA-approved medications for the treatment of opioid use disorder (OUD). Naltrexone, acamprosate, and disulfiram are FDA-approved medications for the treatment of alcohol use disorder (AUD). These medications are effective in reducing substance use and improving recovery outcomes. Patient Choice Matters.…

Read More

Issue Brief: Treating Opioid Use Disorder in Justice-Involved Populations

Download the Issue Brief (PDF) Opioid use disorder (OUD) is a medical condition that is treatable. Individuals involved in the criminal justice system should be screened for OUD. Anyone with moderate to severe OUD should have access to medication treatment for OUD in all criminal justice settings and upon release. OUD is a treatable illness,…

Read More